Moore W M, Webber R K, Fok K F, Jerome G M, Kornmeier C M, Tjoeng F S, Currie M G
Department of Inflammatory Diseases Research, G. D. Searle Research and Development, Monsanto Company, St. Louis, MO 63167, USA.
Bioorg Med Chem. 1996 Sep;4(9):1559-64. doi: 10.1016/0968-0896(96)00148-4.
Identification of potent and selective inhibitors of inducible nitric oxide synthase (NOS) is of great interest because of their therapeutic potential for treatment of diseases mediated by excess production of nitric oxide. We present here a comparison of potency and selectivity for amino acid and nonamino acid based compounds as inhibitors of human inducible, human endothelial constitutive and human neuronal constitutive NOS isoforms. In addition, a novel series of substituted amidines has been identified as NOS inhibitors. 2-Methylthioacetamidine and 2-thienylcarbamidine were the most potent of the series examined with IC50 values of 3.9 and 2.9 microM for human neuronal constitutive NOS. Cyclopropylcarbamidine and 2-thienylcarbamidine were the most potent inhibitors for human inducible NOS with IC50 values of 5.2 and 6.5 microM, respectively. These substituted amidines represent a new class of NOS inhibitors and provide a foundation for potential therapeutic agents.
由于诱导型一氧化氮合酶(NOS)的强效和选择性抑制剂在治疗由一氧化氮过量产生介导的疾病方面具有治疗潜力,因此对其进行鉴定备受关注。我们在此展示了基于氨基酸和非氨基酸的化合物作为人诱导型、人内皮组成型和人神经元组成型NOS亚型抑制剂的效力和选择性比较。此外,已鉴定出一系列新型取代脒作为NOS抑制剂。在所研究的系列中,2-甲硫基乙脒和2-噻吩基甲脒效力最强,对人神经元组成型NOS的IC50值分别为3.9和2.9微摩尔。环丙基甲脒和2-噻吩基甲脒是对人诱导型NOS最有效的抑制剂,IC50值分别为5.2和6.5微摩尔。这些取代脒代表了一类新型的NOS抑制剂,并为潜在治疗药物奠定了基础。